Haifeng Wang

852 total citations
35 papers, 523 citations indexed

About

Haifeng Wang is a scholar working on Cancer Research, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Haifeng Wang has authored 35 papers receiving a total of 523 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Cancer Research, 24 papers in Molecular Biology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Haifeng Wang's work include Cancer-related molecular mechanisms research (22 papers), MicroRNA in disease regulation (16 papers) and RNA modifications and cancer (13 papers). Haifeng Wang is often cited by papers focused on Cancer-related molecular mechanisms research (22 papers), MicroRNA in disease regulation (16 papers) and RNA modifications and cancer (13 papers). Haifeng Wang collaborates with scholars based in China, Japan and United States. Haifeng Wang's co-authors include Jiansong Wang, Yong Tang, Kun Liu, Yanli Qu, Zhenqiang Sun, Xianbo Yu, Mingxia Ding, Dongxiao Ding, Wei Zhang and Hui Zhan and has published in prestigious journals such as Nature Communications, Journal of Agricultural and Food Chemistry and Gene.

In The Last Decade

Haifeng Wang

34 papers receiving 519 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Haifeng Wang China 15 389 313 42 42 41 35 523
Baofei Jiang China 13 315 0.8× 200 0.6× 63 1.5× 67 1.6× 69 1.7× 20 482
Liming Xie China 12 435 1.1× 372 1.2× 25 0.6× 50 1.2× 56 1.4× 17 529
Shanshan Zhao China 13 351 0.9× 258 0.8× 47 1.1× 65 1.5× 40 1.0× 27 486
Cecilia Bica Romania 12 461 1.2× 377 1.2× 21 0.5× 66 1.6× 76 1.9× 22 588
Guang‐Bin Sun China 11 371 1.0× 212 0.7× 45 1.1× 46 1.1× 99 2.4× 25 534
Amir Sadra Zangouei Iran 12 306 0.8× 249 0.8× 28 0.7× 35 0.8× 48 1.2× 28 397
Xiaohong Du China 12 237 0.6× 166 0.5× 48 1.1× 49 1.2× 58 1.4× 19 374
Yuting Kuang China 10 241 0.6× 187 0.6× 28 0.7× 35 0.8× 39 1.0× 20 386

Countries citing papers authored by Haifeng Wang

Since Specialization
Citations

This map shows the geographic impact of Haifeng Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Haifeng Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Haifeng Wang more than expected).

Fields of papers citing papers by Haifeng Wang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Haifeng Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Haifeng Wang. The network helps show where Haifeng Wang may publish in the future.

Co-authorship network of co-authors of Haifeng Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Haifeng Wang. A scholar is included among the top collaborators of Haifeng Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Haifeng Wang. Haifeng Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chen, Junhao, et al.. (2025). Roles and therapeutic potential of the SLC family in prostate cancer—literature review. BMC Urology. 25(1). 32–32. 1 indexed citations
2.
Wang, Haifeng, Chao Lin, Lei Tan, et al.. (2025). Atomic Ga triggers spatiotemporal coordination of oxygen radicals for efficient water oxidation on crystalline RuO2. Nature Communications. 16(1). 3976–3976. 15 indexed citations
3.
Zhao, Zhe, Chaofeng Ma, Xia Yang, et al.. (2025). miR‐92a aggravates metabolic syndrome via KLF2/miR‐483 axis. Journal of Diabetes Investigation. 16(5). 893–906. 2 indexed citations
6.
Bao, Lingling, et al.. (2023). Exosomal miRNA-profiling of pleural effusion in lung adenocarcinoma and tuberculosis. Frontiers in Surgery. 9. 1050242–1050242. 9 indexed citations
7.
Zhou, Shengjun, et al.. (2022). The global change of gene expression pattern caused by PTEN mutation affects the prognosis of glioblastoma. Frontiers in Oncology. 12. 952521–952521. 4 indexed citations
8.
Li, Yanan, et al.. (2022). Long Noncoding RNA HAGLROS Promotes the Malignant Progression of Bladder Cancer by Regulating the miR-330-5p/SPRR1B Axis. Frontiers in Oncology. 12. 876090–876090. 5 indexed citations
9.
Cui, Yanjun, et al.. (2021). Crosstalk between Endoplasmic Reticulum Stress and Oxidative Stress in Heat Exposure-Induced Apoptosis Is Dependent on the ATF4–CHOP–CHAC1 Signal Pathway in IPEC-J2 Cells. Journal of Agricultural and Food Chemistry. 69(51). 15495–15511. 42 indexed citations
10.
Ying, Junjie, et al.. (2021). miR-342-3p Regulates the Proliferation and Apoptosis of NSCLC Cells by Targeting BCL-2. Technology in Cancer Research & Treatment. 20. 2203783081–2203783081. 19 indexed citations
11.
Liu, Xue‐Wei, Zheng Sun, & Haifeng Wang. (2020). Metformin alleviates experimental colitis in mice by up-regulating TGF-β signaling. Biotechnic & Histochemistry. 96(2). 146–152. 17 indexed citations
12.
Wang, Haifeng, Min Guo, Dongxiao Ding, Yang Feng, & Zhongjie Chen. (2020). <p>Long Non-Coding RNA NNT-AS1 Contributes to Cisplatin Resistance via miR-1236-3p/ATG7 Axis in Lung Cancer Cells</p>. OncoTargets and Therapy. Volume 13. 3641–3652. 20 indexed citations
13.
Liu, Hui, Pei Li, Haifeng Wang, et al.. (2020). miR-936 Suppresses Cell Proliferation, Invasion, and Drug Resistance of Laryngeal Squamous Cell Carcinoma and Targets GPR78. Frontiers in Oncology. 10. 60–60. 33 indexed citations
14.
Fu, Shi, Ting Luan, Changyi Jiang, et al.. (2019). miR-3622a promotes proliferation and invasion of bladder cancer cells by downregulating LASS2. Gene. 701. 23–31. 15 indexed citations
15.
Wang, Haifeng, Lin Chen, Jing Luo, & Hongxuan He. (2019). NP and NS1 proteins of H5N1 virus significantly upregulated IFITM1, IFITM2, and IFITM3 in A549 cells. African Health Sciences. 19(1). 1402–1402. 5 indexed citations
16.
Liu, Zhenhua, Haifeng Wang, Lian Zhang, et al.. (2019). Metabolic syndrome is associated with improved cancer-specific survival in patients with localized clear cell renal cell carcinoma. Translational Andrology and Urology. 8(5). 507–518. 8 indexed citations
17.
Zhang, Lingyu, Tiantian Chen, Lei Yan, et al.. (2019). MiR-155-3p acts as a tumor suppressor and reverses paclitaxel resistance via negative regulation of MYD88 in human breast cancer. Gene. 700. 85–95. 33 indexed citations
18.
Wang, Yangyang, Haifeng Wang, Sulian Chen, et al.. (2017). N-peptide of vMIP-II reverses paclitaxel-resistance by regulating miRNA-335 in breast cancer. International Journal of Oncology. 51(3). 918–930. 11 indexed citations
19.
Wang, Haifeng, et al.. (2016). MicroRNA-92 promotes invasion and chemoresistance by targeting GSK3β and activating Wnt signaling in bladder cancer cells. Tumor Biology. 37(12). 16295–16304. 22 indexed citations
20.
Wang, Haifeng, Wei Zhang, Mingxia Ding, et al.. (2015). miR-9 promotes cell proliferation and inhibits apoptosis by targeting LASS2 in bladder cancer. Tumor Biology. 36(12). 9631–9640. 59 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026